1
|
Teshima K, Ikeda S, Abe K, Yamada M, Takahashi N. Acute Myeloid Leukemia Harboring the t(16;21)(p11;q22) Translocation Treated With Venetoclax Plus Azacitidine After Cord Blood Transplantation. Cureus 2023; 15:e42215. [PMID: 37602052 PMCID: PMC10439837 DOI: 10.7759/cureus.42215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/20/2023] [Indexed: 08/22/2023] Open
Abstract
A 62-year-old female was diagnosed with acute myeloid leukemia (AML) with t(16;21)(p11;q22). She achieved complete hematological remission after induction therapy and underwent umbilical cord blood stem cell transplantation (CBT). At 150 days after the CBT, a bone marrow examination revealed relapse. We treated the patient with venetoclax plus azacitidine as salvage therapy. After five cycles of venetoclax and azacitidine therapy, the patient died due to disease progression. The prognosis of AML with t(16;21)(p11;q22) is very poor owing to the high rate of early relapse even after hematopoietic stem cell transplantation. Therefore, a novel therapeutic approach is required to improve patient outcomes.
Collapse
Affiliation(s)
| | - Sho Ikeda
- Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, JPN
| | - Ko Abe
- Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, JPN
| | - Masahiro Yamada
- Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, JPN
| | - Naoto Takahashi
- Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, JPN
| |
Collapse
|
2
|
Morris VS, Ghazi H, Fletcher DM, Guinn BA. A Direct Comparison, and Prioritisation, of the Immunotherapeutic Targets Expressed by Adult and Paediatric Acute Myeloid Leukaemia Cells: A Systematic Review and Meta-Analysis. Int J Mol Sci 2023; 24:9667. [PMID: 37298623 PMCID: PMC10253696 DOI: 10.3390/ijms24119667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2023] [Revised: 05/27/2023] [Accepted: 05/29/2023] [Indexed: 06/12/2023] Open
Abstract
Acute myeloid leukaemia (AML) is characterized by impaired myeloid differentiation resulting in an accumulation of immature blasts in the bone marrow and peripheral blood. Although AML can occur at any age, the incidence peaks at age 65. The pathobiology of AML also varies with age with associated differences in incidence, as well as the frequency of cytogenetic change and somatic mutations. In addition, 5-year survival rates in paediatrics are 60-75% but fall to 5-15% in older AML patients. This systematic review aimed to determine whether the altered genes in AML affect the same molecular pathways, indifferent of patient age, and, therefore, whether patients could benefit from the repurposing drugs or the use of the same immunotherapeutic strategies across age boundaries to prevent relapse. Using a PICO framework and PRISMA-P checklist, relevant publications were identified using five literature databases and assessed against an inclusion criteria, leaving 36 articles, and 71 targets for therapy, for further analysis. QUADAS-2 was used to determine the risk of bias and perform a quality control step. We then priority-ranked the list of cancer antigens based on predefined and pre-weighted objective criteria as part of an analytical hierarchy process used for dealing with complex decisions. This organized the antigens according to their potential to act as targets for the immunotherapy of AML, a treatment that offers an opportunity to remove residual leukaemia cells at first remission and improve survival rates. It was found that 80% of the top 20 antigens identified in paediatric AML were also within the 20 highest scoring immunotherapy targets in adult AML. To analyse the relationships between the targets and their link to different molecular pathways, PANTHER and STRING analyses were performed on the 20 highest scoring immunotherapy targets for both adult and paediatric AML. There were many similarities in the PANTHER and STRING results, including the most prominent pathways being angiogenesis and inflammation mediated by chemokine and cytokine signalling pathways. The coincidence of targets suggests that the repurposing of immunotherapy drugs across age boundaries could benefit AML patients, especially when used in combination with conventional therapies. However, due to cost implications, we would recommend that efforts are focused on ways to target the highest scoring antigens, such as WT1, NRAS, IDH1 and TP53, although in the future other candidates may prove successful.
Collapse
Affiliation(s)
- Vanessa S. Morris
- Department of Chemistry and Biochemistry, University of Hull, Kingston upon Hull HU6 7RX, UK;
| | - Hanya Ghazi
- Hull York Medical School, University of Hull, Kingston upon Hull HU6 7RX, UK;
| | - Daniel M. Fletcher
- Centre for Biomedicine, Hull York Medical School, Kingston upon Hull HU6 7RX, UK;
| | - Barbara-ann Guinn
- Centre for Biomedicine, Hull York Medical School, Kingston upon Hull HU6 7RX, UK;
| |
Collapse
|
3
|
Liu T, Guo Q, Zheng S, Liu Y, Yang H, Zhao M, Yao L, Zeng K, Tu P. Cephalotaxine Inhibits the Survival of Leukemia Cells by Activating Mitochondrial Apoptosis Pathway and Inhibiting Autophagy Flow. Molecules 2021; 26:molecules26102996. [PMID: 34070111 PMCID: PMC8158396 DOI: 10.3390/molecules26102996] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2021] [Revised: 05/11/2021] [Accepted: 05/13/2021] [Indexed: 01/01/2023] Open
Abstract
Cephalotaxine (CET) is a natural alkaloid with potent antileukemia effects. However, its underlying molecular mechanism has not been well understood. In this study, we verified that CET significantly inhibited the viability of various leukemia cells, including HL-60, NB4, Jurkat, K562, Raji and MOLT-4. RNA-sequencing and bioinformatics analysis revealed that CET causes mitochondrial function change. Mechanism research indicated that CET activated the mitochondrial apoptosis pathway by reducing the mitochondrial membrane potential, downregulating anti-apoptotic Bcl-2 protein and upregulating pro-apoptotic Bak protein. In addition, the autophagy signaling pathway was highly enriched by RNA-seq analysis. Then, we found that CET blocked the fluorescence colocation of MitoTracker Green and LysoTracker Red and upregulated the level of LC3-II and p62, which indicated that autophagy flow was impaired. Further results demonstrated that CET could impair lysosomal acidification and block autophagy flow. Finally, inhibiting autophagy flow could aggravate apoptosis of HL-60 cells induced by CET. In summary, this study demonstrated that CET exerted antileukemia effects through activation of the mitochondria-dependent pathway and by impairing autophagy flow. Our research provides new insights into the molecular mechanisms of CET in the treatment of leukemia.
Collapse
Affiliation(s)
- Tingting Liu
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China;
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; (Q.G.); (S.Z.); (Y.L.); (H.Y.); (M.Z.); (L.Y.)
| | - Qiang Guo
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; (Q.G.); (S.Z.); (Y.L.); (H.Y.); (M.Z.); (L.Y.)
| | - Shuze Zheng
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; (Q.G.); (S.Z.); (Y.L.); (H.Y.); (M.Z.); (L.Y.)
| | - Yang Liu
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; (Q.G.); (S.Z.); (Y.L.); (H.Y.); (M.Z.); (L.Y.)
| | - Heng Yang
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; (Q.G.); (S.Z.); (Y.L.); (H.Y.); (M.Z.); (L.Y.)
| | - Meimei Zhao
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; (Q.G.); (S.Z.); (Y.L.); (H.Y.); (M.Z.); (L.Y.)
| | - Lu Yao
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; (Q.G.); (S.Z.); (Y.L.); (H.Y.); (M.Z.); (L.Y.)
| | - Kewu Zeng
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; (Q.G.); (S.Z.); (Y.L.); (H.Y.); (M.Z.); (L.Y.)
- Correspondence: (K.Z.); (P.T.)
| | - Pengfei Tu
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China;
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; (Q.G.); (S.Z.); (Y.L.); (H.Y.); (M.Z.); (L.Y.)
- Correspondence: (K.Z.); (P.T.)
| |
Collapse
|
4
|
Liu Y, Shen J, Awal Issah M, Liu T, Zhou H, Fu H. CD56-positive diffuse large B-cell lymphoma/leukemia with BCL6/MYC double-hit and multiple gene mutations: an indicator of poor prognosis? J Int Med Res 2021; 48:300060520918087. [PMID: 32363958 PMCID: PMC7218936 DOI: 10.1177/0300060520918087] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common adult non-Hodgkin lymphoma (NHL) and is highly invasive, with a poor prognosis. The main clinical treatment for DLBCL involves chemotherapy or a combination of chemotherapy and targeted drugs. CD56 expression is considered as an indicator of poor prognosis in patients with acute myeloid leukemia and anaplastic large cell lymphoma; however, its role in DLBCL remains unclear. We report on a patient with CD56-positive DLBCL/leukemia with BCL6/MYC double-hit, and DDX3X, LRP1B, SIN3A, and GNA13 gene mutations (stage IVA, prognostic index aaIPI = 2 points). The patient was treated with cyclophosphamide and prednisone pre-chemotherapy plus R-Hyper-CVAD AB and DA-EPOCH regimens. Lumbar puncture combined with intrathecal injection was performed to prevent central nervous system infiltration during hospitalization, and complete remission was confirmed. We also reviewed the literature to clarify the relevance of the unique clinical features associated with this case.
Collapse
Affiliation(s)
- Yanquan Liu
- Department of Hematology, Fujian Medical University Union Hospital, Fujian Institute of Hematology, National and Fujian Provincial Key Laboratory of Hematology, Fuzhou, Fujian province, China
| | - Jianzhen Shen
- Department of Hematology, Fujian Medical University Union Hospital, Fujian Institute of Hematology, National and Fujian Provincial Key Laboratory of Hematology, Fuzhou, Fujian province, China
| | - M Awal Issah
- Department of Hematology, Fujian Medical University Union Hospital, Fujian Institute of Hematology, National and Fujian Provincial Key Laboratory of Hematology, Fuzhou, Fujian province, China
| | - Tingbo Liu
- Department of Hematology, Fujian Medical University Union Hospital, Fujian Institute of Hematology, National and Fujian Provincial Key Laboratory of Hematology, Fuzhou, Fujian province, China
| | - Huarong Zhou
- Department of Hematology, Fujian Medical University Union Hospital, Fujian Institute of Hematology, National and Fujian Provincial Key Laboratory of Hematology, Fuzhou, Fujian province, China
| | - Haiying Fu
- Department of Hematology, Fujian Medical University Union Hospital, Fujian Institute of Hematology, National and Fujian Provincial Key Laboratory of Hematology, Fuzhou, Fujian province, China
| |
Collapse
|
5
|
Shang L, Chen X, Liu Y, Cai X, Shi Y, Shi L, Li Y, Song Z, Zheng B, Sun W, Ru K, Mi Y, Wang J, Wang H. The immunophenotypic characteristics and flow cytometric scoring system of acute myeloid leukemia with t(8;21) (q22;q22); RUNX1-RUNX1T1. Int J Lab Hematol 2018; 41:23-31. [PMID: 30264491 DOI: 10.1111/ijlh.12916] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2018] [Revised: 06/26/2018] [Accepted: 07/19/2018] [Indexed: 01/29/2023]
Abstract
INTRODUCTION The translocation t(8;21) is one of the most frequent chromosome translocations in AML. Molecular (cyto)genetics is regarded as the gold standard for diagnosis. However, due to the complicated variety of AML-related genetic abnormalities, comprehensive screening for all of these abnormalities may not be cost-effective. Therefore, a flow cytometric (FC) scoring system was generated in this study for rapid screening and diagnosis of t(8;21)AML. METHODS The immunophenotypic characteristics of leukemic cells and neutrophils in cases with t(8;21) AML or other subtypes of AML were analyzed to find a method for the flow diagnosis of t(8;21) AML. RESULTS In this study, we picked six FC features pointing to the diagnosis of t(8;21) AML: The blasts show high-intensity expression of CD34; aberrant expression of CD19, cCD79a, and CD56 in myeloblasts; co-expression of CD56 in neutrophils, especially in immature neutrophils; and a maturity disturbance in granulocytes. A six-point score was devised using these features. By ROC analysis, the AUC was 0.952, and the sensitivity, specificity, PPV, and NPV were 0.86, 0.90. 0.91, and 0.84 when the score was ≥3 points. The score was then prospectively validated on an independent cohort, and the AUC of the ROC curve for the validation cohort was 0.975. When the cutoff value was set at 3, the obtained sensitivity and specificity values were 0.91 and 0.94, respectively. CONCLUSIONS The FC score described can be used for the identification and rapid screening of t(8;21) AML.
Collapse
Affiliation(s)
- Lei Shang
- Department of Hematopathology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
| | - Xuejing Chen
- Department of Hematopathology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
| | - Yan Liu
- Department of Hematopathology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
| | - Xiaojin Cai
- Department of Hematopathology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
| | - Yin Shi
- Department of Hematopathology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
| | - Lihui Shi
- Department of Hematopathology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
| | - Yuanyuan Li
- Department of Hematopathology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
| | - Zhen Song
- Medical Service Division, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
| | - Bin Zheng
- Department of Hematopathology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
| | - Wanchen Sun
- Department of Hematopathology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
| | - Kun Ru
- Department of Hematopathology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
| | - Yingchang Mi
- Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
| | - Jianxiang Wang
- Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
| | - Huijun Wang
- Department of Hematopathology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
| |
Collapse
|
6
|
Clinicopathological, Cytogenetic, and Prognostic Analysis of 131 Myeloid Sarcoma Patients. Am J Surg Pathol 2016; 40:1473-1483. [DOI: 10.1097/pas.0000000000000727] [Citation(s) in RCA: 64] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
7
|
Wu S, Yang S, Zhu L, Wang Y, Zhang Y, Zhou J, Li D. Prognosis of Patients With de novo Acute Myeloid Leukemia Resistant to Initial Induction Chemotherapy. Am J Med Sci 2016; 351:473-9. [DOI: 10.1016/j.amjms.2016.02.034] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2015] [Accepted: 12/04/2015] [Indexed: 12/19/2022]
|
8
|
Coelho-Silva JL, Carvalho LE, Oliveira MM, Franca-Neto PL, Andrade AT, Lima AS, Bezerra MF, Lima MM, Neves MA, Fonseca JM, Barros-Correia MC, Machado CG, Bezerra MA, Matos DM, Lucena-Araujo AR. Prognostic importance of CD56 expression in intermediate risk acute myeloid leukaemia. Br J Haematol 2016; 176:498-501. [DOI: 10.1111/bjh.13971] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
| | - Luany E Carvalho
- Division of Haematology; Centre of Haematology and Haemotherapy of Ceara; Fortaleza Brazil
| | - Mayara M Oliveira
- Department of Genetics; Federal University of Pernambuco; Recife Brazil
| | | | | | - Aleide S Lima
- Department of Genetics; Federal University of Pernambuco; Recife Brazil
| | - Matheus F Bezerra
- Department of Genetics; Federal University of Pernambuco; Recife Brazil
| | - Marinus M Lima
- Department of Internal Medicine; Cancer Hospital of Pernambuco; Recife Brazil
| | - Maria A Neves
- Department of Internal Medicine; Haematology and Haemotherapy Foundation of Pernambuco; Recife Brazil
| | - Julia M Fonseca
- Department of Internal Medicine; Haematology and Haemotherapy Foundation of Pernambuco; Recife Brazil
| | - Maria C Barros-Correia
- Department of Internal Medicine; Haematology and Haemotherapy Foundation of Pernambuco; Recife Brazil
| | - Cintia G Machado
- Department of Internal Medicine; Haematology and Haemotherapy Foundation of Pernambuco; Recife Brazil
| | - Marcos A Bezerra
- Department of Genetics; Federal University of Pernambuco; Recife Brazil
| | - Daniel M Matos
- Division of Haematology; Centre of Haematology and Haemotherapy of Ceara; Fortaleza Brazil
| | | |
Collapse
|
9
|
Nakase K, Kita K, Kyo T, Ueda T, Tanaka I, Katayama N. Prognostic Relevance of Cytokine Receptor Expression in Acute Myeloid Leukemia: Interleukin-2 Receptor α-Chain (CD25) Expression Predicts a Poor Prognosis. PLoS One 2015; 10:e0128998. [PMID: 26375984 PMCID: PMC4573326 DOI: 10.1371/journal.pone.0128998] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2015] [Accepted: 05/04/2015] [Indexed: 11/30/2022] Open
Abstract
A variety of cytokine/cytokine receptor systems affect the biological behavior of acute leukemia cells. However, little is known about the clinical relevance of cytokine receptor expression in acute myeloid leukemia (AML). We quantitatively examined the expression of interleukin-2 receptor α-chain (IL-2Rα, also known as CD25), IL-2Rβ, IL-3Rα, IL-4Rα, IL-5Rα, IL-6Rα, IL-7Rα, the common β-chain (βc), γc, granulocyte-macrophage colony-stimulating factor (GM-CSF)Rα, G-CSFR, c-fms, c-mpl, c-kit, FLT3, and GP130 in leukemia cells from 767 adult patients with AML by flow cytometry and determined their prevalence and clinical significance. All cytokine receptors examined were expressed at varying levels, whereas the levels of IL-3Rα, GM-CSFRα, IL-2Rα, γc, c-kit, and G-CSFR exhibited a wide spectrum of ≥10,000 sites/cell. In terms of their French-American-British classification types, GM-CSFRα and c-fms were preferentially expressed in M4/M5 patients, G-CSF in M3 patients, and IL-2Rα in non-M3 patients. Elevated levels of IL-3Rα, GM-CSFRα, and IL-2Rα correlated with leukocytosis. In patients ≤60 years old, higher levels of these 3 receptors correlated with poor responses to conventional chemotherapy, but only IL-2Rα was associated with a shorter overall survival. By incorporating IL-2Rα status into cytogenetic risk stratification, we could sort out a significantly adverse-risk cohort from the cytogenetically intermediate-risk group. Analyses with various phenotypical risk markers revealed the expression of IL-2Rα as an independent prognostic indicator in patients with intermediate-risk cytogenetics. These findings were not observed in patients >60 years old. Our results indicate that several cytokine receptors were associated with certain cellular and clinical features, but IL-2Rα alone had prognostic value that provides an additional marker to improve current risk evaluation in AML patients ≤60 years old.
Collapse
Affiliation(s)
- Kazunori Nakase
- Cancer Center, Mie University Hospital, Tsu, Japan
- Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan
- * E-mail:
| | - Kenkichi Kita
- Department of Internal Medicine, Japan Baptist Hospital, Kyoto, Japan
- Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan
| | - Taiichi Kyo
- Fourth Department of Internal Medicine, Hiroshima Red Cross and Atomic-Bomb Survivors Hospital, Hiroshima, Japan
| | - Takanori Ueda
- First Department of Internal Medicine, Fukui University School of Medicine, Fukui, Japan
| | - Isao Tanaka
- Department of Internal Medicine, Suzuka Kaisei Hospital, Suzuka, Japan
| | - Naoyuki Katayama
- Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan
| |
Collapse
|
10
|
Maenhout TM, Moreau E, Van haute I, Desmet S, Deeren D. Minimal Coexpression of CD34+/CD56+ in Acute Promyelocytic Leukemia Is Associated With Relapse. Am J Clin Pathol 2015; 144:347-51. [PMID: 26185322 DOI: 10.1309/ajcpbs3w1rjdgpzu] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Abstract
OBJECTIVES Surface CD56 expression on leukemic cells in acute promyelocytic leukemia (APML) is considered an indicator of poorer outcome even in patients receiving conventional treatment. METHODS In the present case, at initial diagnosis, the hallmark phenotype of APML was found (strong CD33 and cytoplasmic MPO expression, absence of HLA-DR expression). RESULTS Both CD34 and CD56 antigen expression was considered negative. The patient relapsed 3 years after reaching complete remission, and the hallmark surface antigen combination for APML was again found. In contrast, the leukemic cells now clearly coexpressed CD34 and CD56. Retrospective analysis revealed the presence of small CD34+ and CD56+ populations at initial diagnosis (<20%). CONCLUSIONS This case report suggests that the presence of a clone with minimal coexpression of CD34/CD56 in APML at initial diagnosis should not be neglected since it may be associated with earlier relapse.
Collapse
Affiliation(s)
- Thomas M. Maenhout
- Department of Laboratory Medicine, AZ Delta Hospital Roeselare-Menen, Roeselare, Belgium
- Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium
| | - Elisabeth Moreau
- Department of Laboratory Medicine, AZ Delta Hospital Roeselare-Menen, Roeselare, Belgium
| | - Inge Van haute
- Department of Laboratory Medicine, AZ Delta Hospital Roeselare-Menen, Roeselare, Belgium
| | - Stefanie Desmet
- Department of Laboratory Medicine, AZ Delta Hospital Roeselare-Menen, Roeselare, Belgium
| | - Dries Deeren
- Department of Hematology, AZ Delta Hospital Roeselare-Menen, Roeselare, Belgium
| |
Collapse
|
11
|
Prognostic value of CD56 in patients with acute myeloid leukemia: a meta-analysis. J Cancer Res Clin Oncol 2015; 141:1859-70. [DOI: 10.1007/s00432-015-1977-3] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2015] [Accepted: 04/21/2015] [Indexed: 01/11/2023]
|